Literature DB >> 3858884

A system for monocytic differentiation of leukemic cells HL 60 by a short exposure to 1,25-dihydroxycholecalciferol.

G P Studzinski, A K Bhandal, Z S Brelvi.   

Abstract

The human promyelocytic cell line HL 60 can be induced to differentiate toward more mature myeloid or monocytic forms by a variety of agents. This process is thought to require several days of exposure to the inducer, thus making it difficult to identify the early cellular changes which are fundamental to the differentiation program, and to relate the induction to phases of the cell cycle. In order to study the kinetics of leukemic cell differentiation we have developed a system for the induction of rapid monocytic maturation in a subpopulation of HL 60 cells. The cells are exposed to 10(-7) M 1,25-dihydroxycholecalciferol for 4 hr in serum-free medium. Subsequent incubation in a complete medium results in cellular differentiation recognizable by several criteria (phagocytosis, nonspecific esterase reaction, adherence to substratum, cell morphology) beginning at 10 hr from the exposure to the inducer. Approximately 20 hr later 30-40% of the cells in culture show the differentiated phenotype and are capable of phagocytosis. The proportion of differentiated cells in culture decreases thereafter. This system has been utilized to study the expression of c-myc oncogene in relation to the kinetics of maturation, and it was found that the inhibition of the expression of this gene precedes the onset of phenotypic differentiation by approximately 8 hr, is transient, and is accompanied by a brief retardation of cell proliferation, which resumes the normal rate within 24 hr of the exposure to the inducer.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3858884     DOI: 10.3181/00379727-179-42098

Source DB:  PubMed          Journal:  Proc Soc Exp Biol Med        ISSN: 0037-9727


  18 in total

1.  Cooperative antitumor effects of vitamin D3 derivatives and rosemary preparations in a mouse model of myeloid leukemia.

Authors:  Hagar Sharabani; Eugene Izumchenko; Qing Wang; Rita Kreinin; Michael Steiner; Zeev Barvish; Michael Kafka; Yoav Sharoni; Joseph Levy; Milan Uskokovic; George P Studzinski; Michael Danilenko
Journal:  Int J Cancer       Date:  2006-06-15       Impact factor: 7.396

2.  Regulation of C/EBPbeta isoforms by MAPK pathways in HL60 cells induced to differentiate by 1,25-dihydroxyvitamin D3.

Authors:  Ewa Marcinkowska; Edward Garay; Elzbieta Gocek; Agnieszka Chrobak; Xuening Wang; George P Studzinski
Journal:  Exp Cell Res       Date:  2006-04-19       Impact factor: 3.905

3.  MicroRNA-32 upregulation by 1,25-dihydroxyvitamin D3 in human myeloid leukemia cells leads to Bim targeting and inhibition of AraC-induced apoptosis.

Authors:  Elzbieta Gocek; Xuening Wang; Xiuping Liu; Chang-Gong Liu; George P Studzinski
Journal:  Cancer Res       Date:  2011-08-04       Impact factor: 12.701

Review 4.  Vitamin D and differentiation in cancer.

Authors:  Elzbieta Gocek; George P Studzinski
Journal:  Crit Rev Clin Lab Sci       Date:  2009       Impact factor: 6.250

5.  Enhancement of sorafenib-mediated death of Hepatocellular carcinoma cells by Carnosic acid and Vitamin D2 analog combination.

Authors:  Qunfeng Wu; Xuening Wang; Kien Pham; Aesis Luna; George P Studzinski; Chen Liu
Journal:  J Steroid Biochem Mol Biol       Date:  2019-11-05       Impact factor: 4.292

6.  Induction of kinase suppressor of RAS-1(KSR-1) gene by 1, alpha25-dihydroxyvitamin D3 in human leukemia HL60 cells through a vitamin D response element in the 5'-flanking region.

Authors:  X Wang; T-T Wang; J H White; G P Studzinski
Journal:  Oncogene       Date:  2006-05-29       Impact factor: 9.867

7.  The MAPK ERK5, but not ERK1/2, inhibits the progression of monocytic phenotype to the functioning macrophage.

Authors:  Xuening Wang; Stella Pesakhov; Jonathan S Harrison; Michael Kafka; Michael Danilenko; George P Studzinski
Journal:  Exp Cell Res       Date:  2014-10-16       Impact factor: 3.905

8.  Expression of MAP3 kinase COT1 is up-regulated by 1,25-dihydroxyvitamin D3 in parallel with activated c-jun during differentiation of human myeloid leukemia cells.

Authors:  Xuening Wang; George P Studzinski
Journal:  J Steroid Biochem Mol Biol       Date:  2010-03-19       Impact factor: 4.292

9.  1,25-dihydroxyvitamin D3 enhances the apoptotic activity of MDM2 antagonist nutlin-3a in acute myeloid leukemia cells expressing wild-type p53.

Authors:  Thelma Thompson; Michael Andreeff; George P Studzinski; Lyubomir T Vassilev
Journal:  Mol Cancer Ther       Date:  2010-04-20       Impact factor: 6.261

Review 10.  ERK 5/MAPK pathway has a major role in 1α,25-(OH)2 vitamin D3-induced terminal differentiation of myeloid leukemia cells.

Authors:  Xuening Wang; Stella Pesakhov; Ashley Weng; Michael Kafka; Elzbieta Gocek; Mai Nguyen; Jonathan S Harrison; Michael Danilenko; George P Studzinski
Journal:  J Steroid Biochem Mol Biol       Date:  2013-10-26       Impact factor: 4.292

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.